English 日本語

#TakedaPharmaceuticalCompany

List of IR information related to "TakedaPharmaceuticalCompany".

4 IR Posts
1 Companies
11 days ago Last Updated

Filters

Reset
Period:
Importance:
4 IR Posts
4502 Takeda Pharmaceutical Company Limited
2026/02/10
Acceptance of New Drug Application for Oveporexton (TAK-861), a Potential First-in-Class Treatment for Narcolepsy Type 1, by the U.S. Food and Drug Administration and Designation for Priority Review

Takeda Pharmaceutical has announced that the FDA has accepted the new drug application for oveporexton, a treatment for narcolepsy type 1, and designated it for priority review. The target date for review completion is Q3 2026.

#TakedaPharmaceuticalCompany #NewDrugApplication #Narcolepsy
4502 Takeda Pharmaceutical Company Limited
2026/01/20
(Correction) Partial correction regarding “Zasositinib for Plaque Psoriasis, Oral Once Daily Administration Shows Improvement in Skin Lesions and Possibility to Open a New Era of Treatment: Breakthrough Phase 3 Clinical Trial Data”

In the Phase 3 clinical trial of Zasositinib, the primary endpoints were achieved at week 16, with more than half of patients reaching PASI 90 and approximately 30% achieving PASI 100 indicating complete clearance of skin lesions. Safety profile was favorable.

#TakedaPharmaceuticalCompanyLimited #product_announcement #Zasositinib
4502 Takeda Pharmaceutical Company Limited
2025/12/18
Innovative Phase 3 Clinical Trial Data Demonstrates Zasositinib, Administered Once Daily Orally for Plaque Psoriasis, Improves Skin Lesions and Opens a New Era in Treatment

Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #Zasositinib #NewProduct
4502 Takeda Pharmaceutical Company Limited
2025/12/08
Announcement of Long-term rusfertide Data Demonstrating Sustained Hematocrit Control in Polycythemia Vera at the 67th Annual Meeting of the American Society of Hematology (ASH) in Collaboration with Protagonist Therapeutics

Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #rusfertide #NewProduct
Scroll to Top